COMPARE · Data as of August 24, 2026
ANIP vs PFE
Verdict: Side-by-side breakdown using the Bull Rankings model. ANIP scored 80.0, PFE scored 29.5 — ANIP leads.
Compare another set
ANIP
ANI Pharmaceuticals, Inc.
80
$74.17 · $1.7B
fundamentals as of
Score gap
50.5
ANIP leads
PFE
Pfizer Inc.
29.5
$27.97 · $159.4B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestANIP16.2x
- Fastest growthANIP+30.9%
- Strongest balance sheetPFE0.74
- Highest qualityANIP66 / 100
- Largest discount to fair valueANIP-47%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
ANIP
stronger →← stronger
PFE
66
Qualityreturns · margins · balance sheet
66
94
Growthrevenue & earnings expansion
14
82
Valuevaluation vs sector peers
27
ANIP is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ANIP
PFE
$173mC
FCF
$11.0bA-
+30.9%A
Rev
-0.2%D+
1.05C
D/E
0.74C+
16.2xA-
P/E
36.8xC+
1.21B
PEG
2.72C
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
ANIP
PFE
47% below
Price vs fair valuelower is cheaper
13% above
~-7%/yr
Growth the price implies10-yr FCF · lower = less priced in
~3%/yr
+64%
1-yr DCF upside
-4%
+88%
5-yr DCF upside
-11%
+127%
10-yr DCF upside
-20%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ANIP
No notable signals flagged.
PFE
The companies
ANIPANI Pharmaceuticals, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $1.7b. Down 25% from 52-week high of $99.50 — deep drawdown territory. Revenue growing +31% — in hypergrowth territory. 8 sell-side analysts rate this a Buy with a mean 1-yr target of $108.38 (implying +46% upside).
Moat
ROE 18% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 160% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
PFEPfizer Inc.
Why now
Drug Manufacturers - General · market cap $159.4b. Trading near 52-week high of $28.75 — momentum setup, limited technical margin of safety. 26 sell-side analysts rate this a Buy with a mean 1-yr target of $28.61 (implying +2% upside).
Moat
Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong. $159.4b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trading within 3% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Dividend payout 226% of earnings on a 6.1% yield — distribution coverage is thin; one earnings stumble could force a dividend cut. Trailing P/E 37x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ANIP and PFE diverge
On the headline score the gap is 50.5 points in favor of ANIP. The widest single difference is Growth, where ANIP leads by 79.4 points.
- GrowthANIP 93.8 · PFE 14.4ANIP +79.4
- ValueANIP 82.5 · PFE 26.9ANIP +55.6
- QualityANIP 66.2 · PFE 66.1level
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.